Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL into all channels in the United States.
Launch Enables Access To Patients And Providers, Alleviating Supply Chain Constraints
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc (“Cosette”) began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005200/en/
Apurva Saraf, President and CEO, Coesette Pharmaceuticals. (Photo: Business Wire)
This launch will provide much needed access to patients and providers for a product which has been supply constrained. The finished product will be manufactured in the United States.
Apurva Saraf, President and CEO of Cosette Pharma, stated, “This approval and immediate launch demonstrates our ability to continue transforming Cosette, by launching important products through our drug development, supply chain management and manufacturing expertise. This is in addition to a long list of new product launches this year, and is a testament to how we are Innovating Every Day.”
According to IQVIA™, U.S. market annual sales for the 12 months ended October 2022 for Griseofulvin Oral Suspension, 125 mg/5 mL is estimated to be approximately $12 million.
See the Full Prescribing Information and Instructions for Use for Griseofulvin Oral Suspension, 125 mg/5 mL. www.dailymed.com
About Cosette Pharmaceuticals, Inc.:
Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com
Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005200/en/
Contacts
Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com
Source: Cosette Pharmaceuticals, Inc.
Apurva Saraf, President and CEO, Coesette Pharmaceuticals. (Photo: Business Wire)
Griseofulvin Oral Suspension 125mg-5mL. (Photo: Business Wire)
View this news release and multimedia online at:
http://www.businesswire.com/news/home/20221206005200/en
